1. Home
  2. NN vs CDNA Comparison

NN vs CDNA Comparison

Compare NN & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NextNav Inc.

NN

NextNav Inc.

HOLD

Current Price

$16.27

Market Cap

1.9B

Sector

Industrials

ML Signal

HOLD

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$19.92

Market Cap

712.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NN
CDNA
Founded
2007
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
712.2M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
NN
CDNA
Price
$16.27
$19.92
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$26.00
AVG Volume (30 Days)
1.2M
816.3K
Earning Date
11-06-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.22
Revenue
$5,539,000.00
$357,998,000.00
Revenue This Year
N/A
$14.11
Revenue Next Year
N/A
$12.00
P/E Ratio
N/A
$16.92
Revenue Growth
11.61
14.46
52 Week Low
$9.05
$10.96
52 Week High
$18.54
$25.95

Technical Indicators

Market Signals
Indicator
NN
CDNA
Relative Strength Index (RSI) 66.09 66.40
Support Level $13.41 $18.36
Resistance Level $17.20 $19.95
Average True Range (ATR) 0.74 0.87
MACD 0.26 0.16
Stochastic Oscillator 77.31 75.85

Price Performance

Historical Comparison
NN
CDNA

About NN NextNav Inc.

NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation, and Timing services in the absence of GPS.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: